



ASX ANNOUNCEMENT

26 November 2009

Second Core VitroGro® Patent Granted in Australia

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced that the second core patent in the VitroGro® patent family has been granted by the Commonwealth of Australia Patent Office.

As one of the more significant core patents covering the VitroGro® technology, the granting of this patent in Australia and recent allowance in the USA is further good news for Tissue Therapies.

The CEO, Dr Steven Mercer said, "The continued success in the granting of VitroGro® patents around the world is a practical endorsement of the technology and reinforces the commercial value of the VitroGro® IP portfolio and the company."

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com